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Abstract
Background: Amoebiasis is a major public health problem in tropical and subtropical countries.
Although a number of antiamoebic agents are used for its treatment, yet the susceptibility data on
clinical isolates of Entamoeba histolytica and Entamoeba dispar are not available. Therefore, the
present study was aimed to assess the in vitro susceptibility of clinical isolates of E. histolytica and
E. dispar to metronidazole, chloroquine, emetine and tinidazole.
Methods: A total of 45 clinical isolates (15 E. histolytica and 30 E. dispar) were maintained in
polyxenic cultures followed by monoxenic cultures. In vitro drug sensitivity (IC50) of clinical isolates
and standard reference strain of E. histolytica (HM1: IMSS) was assessed by nitro blue tetrazolium
(NBT) reduction assay after exposure to various concentrations of each drug.
Results: The results showed that all clinical isolates had a higher IC50 compared to reference strain
to all the four drugs. E. histolytica isolates appeared to be more susceptible [IC50 (µm) 13.2,26.3,31.2
and 12.4] compared to E. dispar isolates [IC50(µm) 15.6,28.9,32.8 and 13.2] and the reference strain
of E. histolytica [IC50 (µm) 9.5, 15.5, 29.9 and 10.2] to the metronidazole, chloroquine, emetine and
tinidazole respectively.
Conclusions: The results indicate that till date, Entamoeba isolates in India do not seem to be
resistant to the commonly used antiamoebic drugs.
Background
Entamoeba histolytica, is the etiological agent of amoebic
dysentery and amoebic liver abscess (ALA). Worldwide,
40–50 million symptomatic cases of amoebiasis occur
annually and 70,000 to 100,000 deaths due to this infec-
tion [1]. There are two distinct, but morphologically iden-
tical species of Entamoeba: Entamoeba histolytica, which is
pathogenic and Entamoeba dispar, which is non-patho-
genic. E. histolytica, has the capacity to invade intestinal
mucosa resulting in intestinal amoebiasis and cause extra
intestinal amoebiasis [amoebic liver abscess (ALA)] [2].
Infection is primarily treated by instituting antiamoebic
therapy. Drugs of choice for invasive amoebiasis are tissue
active agents, like metronidazole, tinidazole and chloro-
quine or the more toxic emetine derivatives, including
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dehydroemetine. Metronidazole and tinidazole are
derived from 5-nitroimdazole which kill the trophozoites
by alterations in the protoplasmic organelles of the
amoeba, but are ineffective in the treatment of cyst pas-
sers. Chloroquine is derived from 4-aminoquinolines,
which acts on the vegetative forms of the parasite and kills
it by inhibiting DNA synthesis. Emetine, a plant alkaloid,
kills the trophozoites of E. histolytica mainly by inhibiting
protein synthesis.
Indiscriminate use of drugs has led to an increase in the
minimum inhibitory concentration (MIC) of these thera-
peutic agents [3]. Although, drug resistance to E. histolytica
does not appear to be a serious problem, there are occa-
sional reports of failure with metronidazole suggesting
that this could probably be heralding the development of
drug resistance clinically [4]. Recurrence of ALA even after
treatment with metronidazole has been reported and par-
asites may survive in spite of adequate treatment [5].
However, differences in drug sensitivity between strains of
E. histolytica have been reported, indicating that there may
be a small percentage of amoebae which are either resist-
ant to the drug or may even eventually become resistant
due to abuse of antiamoebic agents [6]. Although, earlier
studies have been focused on in vitro sensitivity of the
only axenic strains of E. histolytica [7-9], yet to the best of
our knowledge, studies on in vitro drug susceptibility
studies on clinical isolates of E. histolytica and E. dispar
have not been reported. Therefore, in the present study an
attempt has been made to assess the in vitro activity of
antiamoebic drugs (emetine, chloroquine, metronidazole




Forty-five isolates from patients attending the Out Patient
Departments of Nehru hospital, attached to the Post
Graduate Institute of Medical Education & Research,
Chandigarh, India, identified earlier [10] as either E. histo-
lytica (15) or E. dispar (30) by hexokinase isoenzyme anal-
ysis and by Techlab ELISA were used in the present study.
These have been cultured in modified Boeck and
Drbohlav (NIH) medium [11] followed by Robinson's
medium [12].
Standard reference strain (HM1: IMSS)
Reference strain of E. histolytica (HM1: IMSS) maintained
axenically in TYI-S-33 medium was included as control
[13].
Preparation of antimicrobial agents
The drugs (metronidazole, chloroquine, emetine dihydro-
chloride and tinidazole) used in the study were procured
as pure salt from Sigma-Aldrich Co., St. Louis, MO.,
63178 USA. The stock solutions of drugs (each 0.1 M)
were prepared in dimethyl sulphoxide (DMSO) [14] and
stored at -20°C till use. The stock solutions were diluted
in medium to the required concentration. A starting con-
centration used was 200 µM, which yielded a maximum
concentration in the assay of 17.1 µg/ml metronidazole,
Percentage inhibition of E. histolytica Figure 1
Percentage inhibition of E. histolytica (HM1: IMSS) and clinical 
isolates of E. histolytica and E. dispar by metronidazole
Percentage inhibition of E. histolytica Figure 2
Percentage inhibition of E. histolytica (HM1: IMSS) and clinical 
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51.59 µg/ml chloroquine, 55.3 µg/ml emetine, and 24.7
µg/ml tinidazole.
In vitro drug sensitivity assay
Drug sensitivity to all the compounds was carried out by
nitroblue tetrazolium (NBT) reduction method [15]. Each
clinical isolate was tested in duplicate along with the ref-
erence E. histolytica strain (HM1: IMSS). Amoebae were
harvested from 24 hour old cultures and suspended in
medium. The parasite count was adjusted to 3 × 105 para-
sites/ml in medium by haemocytometer [15].
The assay was carried out in microtiter plates (Grenier bio-
one, Germany). Briefly, in row A 200 µl of drug and in all
other rows (B-H) medium was added and doubling dilu-
tions of the drug were performed down the plate. Final
drug concentration in rows A-H was as follows: 100, 50,
25, 12.5, 6.25, 3.12, 1.6 and 0.8 (µM). Further 100 µl of
parasite suspension (3 × 105/well) was added to all the
rows (A-H). Each test included control (without drug) and
blank wells (medium only). The plates were incubated at
37°C for 4 hrs. The contents of the plates were discarded
and washed with pre warmed Hank's balanced salt solu-
tion (HBSS pH 7.2). Thereafter, 100 µl of NBT/well in
HBSS was added and the plates were incubated at 37°C
for 45 min. followed by aspiration of the contents. Plates
were then washed with HBSS twice and 200 µl/well of
DMSO (100% v/v) was added. Following incubation at
37°C for 10 min, the optical density (OD) was measured
in an ELISA recorder at 540 nm.
The percentage of non-viable organisms, which failed to
metabolize NBT and therefore did not produce the dark
blue formazan product, was determined by applying the
following formula:
Percentage of non-viable organisms at each drug conc. =
Statistical analysis
The mean IC50 values of all clinical isolates against the
four drugs were compared with corresponding IC50 values
of the reference E. histolytica strain (HM1: IMSS). Standard
deviation (SD) was used to indicate the extent of variation
around group mean values. The p value was calculated
using the student's-t test.
Percentage inhibition of E. histolytica Figure 3
Percentage inhibition of E. histolytica (HM1: IMSS) and clinical 
isolates of E. histolytica and E. dispar by emetine Percentage inhibition of E. histolytica Figure 4
Percentage inhibition of E. histolytica (HM1: IMSS) and clinical 
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Results
The IC50 values of emetine, chloroquine, metronidazole
and tinidazole for the 45 clinical isolates [15 E. histolytica
and 30 E. dispar] and the reference strain HM1: IMSS were
determined by the NBT reduction assay. The mean IC50
values were significantly higher (P < 0.001) in E. dispar
isolates to all the four antiamoebic drugs as compared to
the E. histolytica isolates and the reference E. histolytica
strain (Table 1 & Figures 1–4).
Discussion
Treatment failure among amoebiasis patients often raises
the possibility of drug resistance [16]. In the present study
the 15 E. histolytica and 30 E. dispar clinical isolates main-
tained by in vitro cultivation in monoxenic medium were
subjected to drug susceptibility tests against four
antiamoebic drugs: metronidazole, chloroquine, emetine
and tinidazole by NBT reduction assay. E. histolytica refer-
ence strain (HM1: IMSS) was also included in each set of
experiments.
Results showed a significant difference in drug sensitivity
in clinical isolates as compared to the reference strain with
all the four drugs. The mean IC50 values (µm) of the E. his-
tolytica/E.  dispar  isolates against metronidazole, chloro-
quine, emetine and tinidazole were 13.2/15.6, 26.3/28.9,
31.2/32.8 and 12.4/13.2 respectively. The IC50  values
(µm) of the reference strain against all the four respective
drugs were 9.5, 15.5, 29.9 and 10.2. Recently Upcroft &
Upcroft [14] have reported that the MIC values of
metronidazole ranges from 12.5–25 µm for laboratory-
passaged E. histolytica strains. Adagu, et.al. [9] have shown
the mean metronidazole IC50 value as 18.47 µm for the
most susceptible isolates of E. histolytica with a > 30 µm
value as the cut off for resistance. Burchard & Mirelman,
studied in vitro sensitivity to metronidazole and emetine
of non-pathogenic zymodemes and showed that all were
similarly sensitive to both the drugs (1–10 µg/ml) [6]. In
the present study, clinical isolates maintained in monox-
enic culture were used to detect the in vitro sensitivity as
earlier it has been concluded that bacterial flora associated
with the amebae did not significantly interfere with the
test performance and sensitivity values [6].
Although resistance to metronidazole has been reported
against Trichomonas vaginalis [17], Giardia  lamblia [18]
and Leishmania donovani [19], yet to the best of our knowl-
edge there is no documented resistance among clinical
isolates of E. histolytica and E. dispar.
Conclusion
The results of the present study are in agreement with pre-
vious findings [6,9,14], except that there was a signifi-
cantly higher IC50 value of all four drugs to the clinical
isolates as compared to the reference strain. E. dispar iso-
lates showed higher IC50 values when compared to E. his-
tolytica or reference strain. This is the first report of in vitro
drug sensitivity pattern to clinical isolates of E. histolytica
and E. dispar. There is definitely a need to monitor the ran-
dom drug susceptibility among clinical isolates especially
in context to widespread use of metronidazole and
tinidazole, which are available over the counter in many
countries. Increased awareness and continued surveil-
lance for the possible emergence of resistance among clin-
ical isolates is necessary for the ultimate prevention and
control of amoebiasis.
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Table 1: Comparison between 1C50 value of clinical isolates (E. histolytica and E. dispar) vs reference strain (HM1: IMSS)
COMPOUND MEAN IC50 OF CLINICAL ISOLATES (µm ± SD) IC50 VALUE OF REFERENCE 
STRAIN (µm ± SD)
E. histolytica E. dispar
Metronidazole 6.5 ± 0.81***a 15.6 ± 2.12***c 9.5 ± 1.53***b
Chloroquine 18.9 ± 1.39***a 28.9 ± 2.45***c 21.5 ± 1.26***b
Emetine 26.8 ± 1.27***a 32.8 ± 1.68***c 28.0 ± 2.62***b
Tinidazole 8.2 ± 1.09***a 13.2 ± 1.43***c 10.2 ± 0.43***b
Results expressed as mean ± SD from two experiments conducted in duplicate
Student's t-test [*** P < 0.001]
a = Eh Vs Ed Eh – E. histolytica
b = Eh Vs C Ed – E. dispar
c = Ed Vs C C – Reference strain (HM1: IMSS)
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